Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Liabilities (2016 - 2025)

Fate Therapeutics' Total Liabilities history spans 14 years, with the latest figure at $111.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 8.38% year-over-year to $111.8 million; the TTM value through Dec 2025 reached $111.8 million, down 8.38%, while the annual FY2025 figure was $111.8 million, 8.38% down from the prior year.
  • Total Liabilities reached $111.8 million in Q4 2025 per FATE's latest filing, up from $109.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $263.6 million in Q2 2021 to a low of $109.6 million in Q3 2025.
  • Average Total Liabilities over 5 years is $173.6 million, with a median of $145.4 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 149.21% in 2021, then tumbled 39.05% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $242.6 million in 2021, then fell by 8.65% to $221.6 million in 2022, then crashed by 37.82% to $137.8 million in 2023, then dropped by 11.49% to $122.0 million in 2024, then dropped by 8.38% to $111.8 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Total Liabilities are $111.8 million (Q4 2025), $109.6 million (Q3 2025), and $110.3 million (Q2 2025).